A second phase III trial of arhalofenate in combination with febuxostat in patients with chronic gout
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2016
At a glance
- Drugs Arhalofenate (Primary) ; Febuxostat
- Indications Gout
- Focus Registrational; Therapeutic Use
- Sponsors CymaBay Therapeutics
- 09 Aug 2016 According to a CymaBay Therapeutics media release, the company has completed End-of-Phase 2 discussions with the FDA and reached agreement on all of the key elements of the planned Phase 3 program.
- 22 Jan 2016 New trial record
- 20 Jan 2016 According to a CymaBay Therapeutics media release, this is one of the 3 phase III trials that will support registration.